Seven Springs Wealth Group’s Kyntra Bio KYNB Stock Holding History

Seven Springs Wealth Group’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	–	–	172
2020 Q4	$0	Buy	+1	New	+$1.05K	﹤0.01%	259

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seven Springs Wealth Group's KYNB Position: Q1 2021 in Review

Seven Springs Wealth Group sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 1 share.

Seven Springs Wealth Group first reported a position in KYNB in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

Seven Springs Wealth Group reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
Seven Springs Wealth Group sold 1 Kyntra Bio share in Q1 2021.
Seven Springs Wealth Group first reported a position in Kyntra Bio in Q4 2020 and held it in 1 quarter.
Seven Springs Wealth Group's Kyntra Bio position peaked at $0 in Q4 2020.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Seven Springs Wealth Group's 13F filing for Q1 2021, filed 7 May 2021.